SCHEMBL1551528

SCHEMBL1551528

COc1cc(/C=C/C=C(\C#N)C(=O)OCc2ccccc2)cc(OC)c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.60
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
MAPT P10636 3/20 0.53
ALOX5 P09917 5/20 0.51
MET P08581 2/20 0.50
CA12 O43570 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
EGFR P00533 2/20 0.47
ERBB2 P04626 2/20 0.47
ALDH1A1 P00352 1/20 0.45
MCL1 Q07820 1/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1551530 1.00 MAOB (0.60) MAOBKMT2AMEN1MAPTALOX5
SCHEMBL1552823 0.90 MAOB (0.63) MAOBKMT2AMEN1MAPTALOX5
SCHEMBL1552825 0.90 MAOB (0.63) MAOBKMT2AMEN1MAPTALOX5
SCHEMBL4489692 0.82 MCL1 (0.70) MAOBKMT2AMEN1MAPTALOX5
SCHEMBL4489689 0.82 MCL1 (0.70) MAOBKMT2AMEN1MAPTALOX5
SCHEMBL4488546 0.81 APP (0.52) KMT2AMEN1MAPTEGFRALDH1A1
SCHEMBL4488550 0.81 APP (0.52) KMT2AMEN1MAPTEGFRALDH1A1
SCHEMBL1552561 0.81 MAOB (0.69) MAOBKMT2AMEN1MAPTEGFR
SCHEMBL1552227 0.81 MAOB (0.69) MAOBKMT2AMEN1MAPTEGFR
SCHEMBL6030512 0.81 MEN1 (0.78) MAOBKMT2AMEN1MAPTALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467967-B1 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2011-04-27 EP claimed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US claimed
US-20070197660-A1 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2007-08-23 US claimed
EP-1654220-A4 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2006-10-25 EP claimed
EP-1654220-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2006-05-10 EP claimed
US-20050085538-A1 Compounds for modulating cell proliferation HOSPITAL FOR SICK CHILDREN, THE (CA) 2005-04-21 US claimed
WO-2005012234-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2005-02-10 WO claimed
EP-1467967-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2004-10-20 EP claimed
WO-2003062190-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2003-07-31 WO claimed
EP-1467967-B1 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2011-04-27 EP disclosed
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
EP-1551381-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR The Hospital for Sick Children (CA) 2005-07-13 EP disclosed
US-20050085538-A1 Compounds for modulating cell proliferation HOSPITAL FOR SICK CHILDREN, THE (CA) 2005-04-21 US disclosed
WO-2005012234-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2005-02-10 WO disclosed
EP-1467967-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2004-10-20 EP disclosed
WO-2004032911-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR THE HOSPITAL FOR SICK CHILDREN (CA) 2004-04-22 WO disclosed
WO-2003062190-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085538-A1 Compounds for modulating cell proliferation CCNO, CCNY, CCND3 MAOB 1268/4885KMT2A 3663/4885MEN1 1955/4885
US-20070197660-A1 Compounds for modulating cell proliferation CCND3, CCNO, WNT3 MAOB 2008/4885KMT2A 3844/4885MEN1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.